Program
zorifertinib
Also written as “AZD3759” and “Zorifertinib and Osimertinib Combination Therapy”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Meningeal Carcinomatosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alpha Biopharma (Jiangsu) | 21 open or running | phase 3since Aug 22, 2018 | Aug 22, 2018 | Apr 23, 2028phase 1 · NCT07361705 |
| AstraZeneca | 10 open or running | phase 1since Aug 20, 2014 | Aug 20, 2014 | none ahead |
| LYZZ Alpha | 10 open or running | phase 2since Nov 16, 2017 | Nov 16, 2017 | none ahead |
Also a collaborator on its studies: Tigermed Consulting.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2014First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT02228369 · 108 enrolled · United States, Australia, Korea, Republic of and more
- Nov 16, 2017LYZZ Alpha’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to LYZZ AlphaLYZZ Alpha · NCT03360929 · 15 enrolled · China
- Aug 22, 2018Alpha Biopharma (Jiangsu)’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to Alpha Biopharma (Jiangsu)Alpha Biopharma (Jiangsu) · NCT03653546 · 492 enrolled · China, Singapore, South Korea and more
- Dec 4, 2025Phase 1 study in Meningeal CarcinomatosisAlpha Biopharma (Jiangsu) · NCT07361705 · 42 planned · China
Ahead
- Apr 23, 2028Primary completion: phase 1 study in Meningeal CarcinomatosisAlpha Biopharma (Jiangsu) · NCT07361705
TargetBeta
“An orally available inhibitor of the epidermal growth factor receptor (EGFR), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07361705Meningeal Carcinomatosis · China | 1 | Recruiting | Alpha Biopharma (Jiangsu) | Apr 23, 2028 | 42 |
| NCT03653546Carcinoma, Non-Small-Cell Lung · China, Singapore, South Korea and more | 3 | Completed | Alpha Biopharma (Jiangsu) | Jul 12, 2022 | 492 |
| NCT03360929Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | LYZZ Alpha | Nov 13, 2020 | 15 |
| NCT02228369Carcinoma, Non-Small-Cell Lung · United States, Australia, Korea, Republic of and more | 1 | Completed | AstraZeneca | Aug 19, 2017 | 108 |
How it is read
Names in the registry
- “AZD3759”, 3 entries
- “Zorifertinib and Osimertinib Combination Therapy”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Meningeal Carcinomatosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.